Exosome-Based Platform Can Enrich for Cancer-Specific Exosomes; New Data Demonstrates mRNA Signature in Exosomes Derived from Metastatic Melanoma Patients Treated with Ipilimumab; Early Signature Changes Associated with Improved Progression-Free Survival

On November 9, 2015, Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, announced new data demonstrating the novel ability of its proprietary exosomal RNA (exoRNA) technology platform to enrich for cancer-specific exosomes in order to more precisely determine tumor-specific gene changes in response to immunotherapy treatment. The data were presented on Sunday, November 8, in a late-breaking poster session at the 26th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place November 5-9 in Boston, Massachusetts. The session was entitled, “Early Exosome mRNA Changes Are Associated with Improved Progression-Free survival of Metastatic Melanoma Patients on Ipilimumab: Identification of a Novel Exosome mRNA Signature of Ipilimumab Response.” “These data are quite exciting, as they represent the continued evolution and maturation of how we can potentially utilize exosomes to derive critical molecular information about cancer with the end goal of improving treatment and outcomes for patients,” said Keith Flaherty (photo), M.D., Director, Henri and Belinda Termeer Center for Targeted Therapies at the Massachusetts General Hospital (MGH) Cancer Center in Boston, Massachusetts, and a co-author of the abstract. “The ability of the Exosome Diagnostics platform to pinpoint tumor-specific gene changes associated with immunotherapy treatment responses in exosomes is a key advancement.
Login Or Register To Read Full Story